Dr. David Sinclair
Livelong Flash Update
Today, we’re bringing you a flash news update in the biotech and anti-aging space. Researchers share hopeful research on life extension, but it’s being met with a not-so-uncommon skepticism from others in the space.
Our top story is on Dr. David Sinclair’s latest claim.
Harvard geneticist David Sinclair, recognized for his work on aging, says his team has developed a drug designed to “reverse aging” across the entire body.
If true, the oral drug (SL-100) could be the first therapy shown to do this in humans. But without complete evidence that it works—and no real agreement on how best to measure it—many unanswered questions remain.
Sinclair’s approach uses chemical reprogramming, a method that pushes cells toward a more youthful state by mimicking signals present during early development. Unlike gene therapy—which typically targets a single tissue—SL-100 uses the bloodstream to hit targets throughout the body. But it’s still been a challenge to do this safely in humans.
Real anti-aging, or hopeful chemistry?
The scientific response has been cautious. Harvard researcher Vadim Gladyshev has published research warning that chemical reprogramming is toxic to mice.
No peer-reviewed animal data has been published. No public, peer-reviewed animal studies show that SL-100 can safely reverse aging.
Sinclair’s track record adds to the skepticism. Having made exaggerated anti-aging claims before—one being that his organization found a drug “proven to reverse aging in dogs” (unfortunately, we’re not there yet!)—it might add some mistrust.
What’s next: Sinclair has suggested the drug could be tested through the XPrize Healthspan competition, a global competition offering $101 million to whichever team can create an innovation that offers a 10-year improvement in immune, cognitive, and muscle function after one year.
We’re staying tuned if Sinclair publishes any preclinical data before human trials begin. It will be interesting to see how XPrize judges evaluate his claims, which haven’t gone through any standard peer review.
The search for the fountain of youth never ends.
Your next read
Scientists just gave the first “age-reversal therapy“ to humans
A separate milestone might offer more promise. Biotech giant Life Biosciences has administered an experimental age-reversal therapy to its first human patient, marking one of the first real-world tests of whether cellular “rejuvenation” can work in people.
The treatment is based on epigenetic reprogramming, an emerging approach designed to reset aging cells to a more youthful state without changing their DNA.
*Up until now, this technology has only shown promise in laboratory and animal studies.
This first-in-human trial marks the beginning of a critical test—whether cellular rejuvenation can move from theory to reality. If successful, it could help launch an entirely new class of therapies aimed not just at treating disease, but at targeting aging itself.
Only at Livelong
Why do men die sooner? Livelong Founder Brad Inman says men need to “ditch the stoicism.”
How you handle failure is directly linked to how well you age. So what can you do about it?
Menopause is a brain event. What does this mean for cognitive health?
What did you think of our first flash news story? Do you think we should keep it going? Let us know in the poll!
How did you enjoy today's newsletter?
The information provided about wellness and health is for general informational and educational purposes only. We are not licensed medical professionals, and the content here should not be considered medical advice. Talk to a doctor before trying any of these suggestions.
